CN107921112A - 调节lgals3bp以治疗系统性红斑狼疮的方法 - Google Patents

调节lgals3bp以治疗系统性红斑狼疮的方法 Download PDF

Info

Publication number
CN107921112A
CN107921112A CN201680050415.7A CN201680050415A CN107921112A CN 107921112 A CN107921112 A CN 107921112A CN 201680050415 A CN201680050415 A CN 201680050415A CN 107921112 A CN107921112 A CN 107921112A
Authority
CN
China
Prior art keywords
lgals3bp
cells
patient
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680050415.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·德马蒂诺
J·德里
J·弗拉奇
N·刘易斯
M·吉内斯特
S·奥吉兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN107921112A publication Critical patent/CN107921112A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680050415.7A 2015-08-31 2016-08-30 调节lgals3bp以治疗系统性红斑狼疮的方法 Pending CN107921112A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212163P 2015-08-31 2015-08-31
US62/212,163 2015-08-31
PCT/US2016/049378 WO2017040464A1 (en) 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CN107921112A true CN107921112A (zh) 2018-04-17

Family

ID=56883878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680050415.7A Pending CN107921112A (zh) 2015-08-31 2016-08-30 调节lgals3bp以治疗系统性红斑狼疮的方法

Country Status (9)

Country Link
US (1) US20180251559A1 (enExample)
EP (1) EP3344283A1 (enExample)
JP (2) JP2018526443A (enExample)
CN (1) CN107921112A (enExample)
AU (1) AU2016317768A1 (enExample)
CA (1) CA2994180A1 (enExample)
HK (1) HK1252815A1 (enExample)
IL (1) IL257755A (enExample)
WO (1) WO2017040464A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
EP4174086A4 (en) * 2020-06-30 2024-07-24 The Asan Foundation ANTIBODIES SPECIFICALLY BINDING TO LGALS3BP AND USE THEREOF
KR102704018B1 (ko) * 2020-06-30 2024-09-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
KR20230160803A (ko) 2021-03-24 2023-11-24 에이지씨 가부시키가이샤 축전 디바이스 전극용 프라이머, 프라이머층 형성용의 조성물, 축전 디바이스용 전극 및 이차 전지
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1572325A (zh) * 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
CN1620309A (zh) * 2001-12-18 2005-05-25 蒙多生物技术实验室 用于结合分子诊断法改进间质性肺疾病的治疗的干扰素γ或甲苯吡啶酮的新型药物组合物
WO2011126833A2 (en) * 2010-03-29 2011-10-13 Massachusetts Institute Of Technology Anti-inflammatory factors
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2012074396A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP2566878A4 (en) * 2010-03-26 2013-10-23 Jolla Inst Allergy Immunolog METHOD OF INHIBITING INFLAMMATORY AND INFLAMMATORY DISEASES BY GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1572325A (zh) * 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
CN1620309A (zh) * 2001-12-18 2005-05-25 蒙多生物技术实验室 用于结合分子诊断法改进间质性肺疾病的治疗的干扰素γ或甲苯吡啶酮的新型药物组合物
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2011126833A2 (en) * 2010-03-29 2011-10-13 Massachusetts Institute Of Technology Anti-inflammatory factors
WO2012074396A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴元胜等: "基因芯片技术分析SLE证候基因表达的初步研究", 《现代中西医结合杂志》 *

Also Published As

Publication number Publication date
JP2021050217A (ja) 2021-04-01
WO2017040464A1 (en) 2017-03-09
HK1252815A1 (zh) 2019-06-06
EP3344283A1 (en) 2018-07-11
CA2994180A1 (en) 2017-03-09
AU2016317768A1 (en) 2018-02-22
IL257755A (en) 2018-04-30
JP2018526443A (ja) 2018-09-13
US20180251559A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
JP2021050217A (ja) 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
US8771689B2 (en) Alpha B-crystallin as a therapy for ischemia or inflammation
WO2003026691A2 (en) Use of hmgb1 for the activation of dendritic cells
JP2009203245A (ja) 免疫複合体関連疾患を処置するための方法および組成物
JP7620988B2 (ja) 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
US20240366736A1 (en) Method for managing pain
EA017999B1 (ru) Композиция, содержащая пептиды основного белка миелина, ее применение и способ лечения или профилактики рассеянного склероза или оптического неврита
Seasons et al. Ultrasound and neuroinflammation: immune modulation via the heat shock response
JP7351835B2 (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
Grohmann et al. The Immunosuppressive Activity of Proinflammatory Cytokines in Experimental Models Potential for Therapeutic Intervention in Autoimmunity
US9718879B2 (en) Methods of treating pain by inhibition of VGF activity
Singh et al. Tuning immune suppression in systemic autoimmunity with self-derived peptides
JP7028761B2 (ja) 免疫調節疾患および障害の治療方法および組成物
US9610326B2 (en) Amyloid beta peptides as therapy for multiple sclerosis
JP2021523892A (ja) Ｏｃａ−ｂペプチドコンジュゲート及び処置方法
JP2013512279A (ja) ＩｇＥ媒介性疾患の処置方法
CA3224757A1 (en) Peptides for the treatment of chronically active autoimmune inflammation
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
John Increased plasma cell differentiation, hyper-responsiveness to TLR9, and loss of peripheral B cell tolerance in mice lacking the transcription factor Ets-1.
Einarsson New Resorption Pathways in Polycaprolactone: Degradation; roles of Mononuclear and Multinucleated Giant Cells
Alferink Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity
US20090317357A1 (en) Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
Schalks Chronic meningeal inflammation as a cause of cortical grey matter pathology in multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252815

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1252815

Country of ref document: HK